Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Barcelona
Clinical trial register · Spain

Clinical Trials in Barcelona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 40 Madrid 37 Seville 23 Valencia 20 Málaga 18
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca188 Merck Sharp & Dohme LLC113 Novartis Pharmaceuticals111 Janssen Research & Development, LLC96 Hoffmann-La Roche85 Clear sponsor filter
Site location
Barcelona40 Madrid37 Seville23 Valencia20 Málaga18
All 55 locations
Target enrolment
to

Trials with a site in Barcelona

40 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
Amgen
Phase 1
160
Málaga, Barcelona, Valencia, Madrid
2026-04-21
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
Barcelona, Madrid
2026-04-08
Active, closed
Amgen
Phase 3
250
Barcelona, A Coruña, Pozuelo de Alarcón, Madrid
2025-12-19
Recruiting
Amgen
Phase 3
750
Málaga, Barcelona, L'Hospitalet de Llobregat, A Coruña, Lugo, Majadahonda, Pamplona, Madrid
2025-11-28
Active, closed
Amgen
Phase 3
250
Barcelona, A Coruña, Pozuelo de Alarcón, Madrid
2025-11-25
Active, closed
Amgen
Phase 3
350
Málaga, Barcelona, Majadahonda, Valencia, Madrid
2025-08-18
Recruiting
Amgen
Phase 1
434
Barcelona, Madrid
2025-07-31
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Santander, Barcelona, Madrid
2025-07-16
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Córdoba, Málaga, Las Palmas de Gran Canaria, Badalona, Barcelona, L'Hospitalet de Llobregat, Lleida, A Coruña
2025-06-25
Active, closed
Amgen
Phase 1
29
Barcelona, Majadahonda, Madrid
2025-05-16
Active, closed
Amgen
Phase 2
252
Las Palmas de Gran Canaria, Barcelona, A Coruña, Madrid
2025-02-26
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Alcorcón, Barcelona, Castilleja de la Cuesta, Dénia, Madrid, Malag, Málaga, Salt
2025-01-13
Active, closed
Amgen
Phase 3
707
Málaga, Seville, Barcelona, Pamplona, Valencia, Madrid
2024-12-09
Active, closed
Amgen
Phase 3
19
Barcelona, Esplugues de Llobregat, Madrid
2024-10-22
Recruiting
Amgen
Phase 1
220
Málaga, Barcelona, Valencia, Madrid
2024-10-07
Active, closed
Amgen
Phase 1
49
Barcelona, Madrid
2024-09-17
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
DrugsABP 234·Pembrolizumab
Amgen
Phase 3
163
A Coruna Galicia, A Coruña, Alicante, Badalona, Barcelona, Jerez de la Frontera, Madrid, Mataró
2024-09-12
Active, closed
Amgen
Phase 3
315
Alicante, Barcelona, Jaén, Madrid, Mataró, Málaga, Oviedo, Seville
2024-09-09
Active, closed
Amgen
Phase 3
563
Málaga, Seville, Barcelona, L'Hospitalet de Llobregat, Pamplona, Valencia, Madrid
2024-06-05
Active, closed
Amgen
Phase 1
120
Seville, Barcelona, Madrid
2024-05-29
Active, closed
Amgen
Phase 3
111
Barakaldo, Barcelona, Esplugues de Llobregat, Getafe, Valencia, Madrid
2024-04-22
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Málaga, Seville, Zaragoza, Las Palmas de Gran Canaria, Badalona, Barcelona, Santiago de Compostela, Majadahonda
2024-02-20
Recruiting
Amgen
Phase 3
750
Málaga, Seville, Zaragoza, Palma de Mallorca, Las Palmas de Gran Canaria, Santander, Valladolid, Barcelona
2023-11-16
Active, closed
Amgen
Phase 3
633
Seville, Badalona, Cáceres, El Palmar, Barcelona, Madrid, Málaga, Valencia
2023-11-02
Active, closed
Amgen
Phase 3
509
Málaga, Zaragoza, Barcelona, A Coruña, Majadahonda, Madrid
2023-05-31
Active, closed
Amgen
Phase 3
7,297
Córdoba, Málaga, Seville, Zaragoza, León, Badalona, Barcelona, L'Hospitalet de Llobregat
2022-12-14
Active, closed
Amgen
Phase 1
184
Badalona, Barcelona, Madrid
2022-08-24
Recruiting
Amgen
Phase 3
60
San Cristóbal de La Laguna, Barcelona, Esplugues de Llobregat, Valencia, Madrid
2022-03-17
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 2
222
Málaga, Barcelona, L'Hospitalet de Llobregat, Majadahonda, Valencia, Madrid
2021-12-01
Active, closed
Amgen
Phase 3
303
Córdoba, Seville, Santander, Salamanca, Badalona, Barcelona, L'Hospitalet de Llobregat, Valencia
2021-11-02
Recruiting
Amgen
Phase 3
60
Seville, Barcelona, Esplugues de Llobregat, Valencia, Madrid
2021-09-09
Active, closed
Amgen
Phase 1/2
181
Seville, Santander, Salamanca, Badalona, Barcelona, Esplugues de Llobregat, L'Hospitalet de Llobregat, Pamplona
2021-01-04
Active, closed
Amgen
Phase 3
135
Barcelona, Madrid, Valencia
2020-12-04
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
Badalona, Barcelona, Córdoba
2020-10-15
Recruiting
Amgen
Phase 1
479
Barcelona, Pamplona, Madrid
2020-03-04
Active, closed
Amgen
Phase 3
145
Granada, Seville, Salamanca, Barcelona, Ourense, Fuenlabrada, Castellon, Madrid
2020-02-26
Recruiting
Amgen
Phase 3
24
Seville, Barcelona
2019-12-20
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DrugsBI 1701963·TNO155·Sotorasib·Afatinib
Amgen
Phase 1
610
Barcelona, L'Hospitalet de Llobregat, Majadahonda, Madrid
2019-12-17
Active, closed
Amgen
Phase 3
457
Seville, Barcelona, Pamplona, Valencia
2019-07-19
Active, closed
Amgen
Phase 1
269
Barcelona, Madrid
2017-12-26
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/barcelona

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies with a site in Barcelona that also match the filters currently applied.

How many clinical trials are recruiting in Barcelona?

12 of the 40 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 28 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Barcelona), 40 studies
PhaseStudiesRecruitingShare
Phase 325662.5%
Phase 111527.5%
Phase 2317.5%
Phase 1/2102.5%

Most active sponsors

Lead sponsors with the most studies (Barcelona)
Lead sponsorStudiesRecruiting
Amgen4012
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.